Upregulation of nonclassical NF-κB has been observed in tumor dendritic cells, improving the synergistic relationship between dendritic cells and CD8+ T cells.[21] RelA, a transcription factor downstream of the classical NF-κB pathway, either increases the resistance of cancer cells to T cell-induced cell death or increases the expression of PD-L1 in ovarian cancer cells.[22,23] Although previous studies have suggested that the members of the PPM family may regulate the NF-κB pathway to influence immunity; the relationship between PPM1M and immunity in pan-cancer is not yet clear. Here, NFKB1 is linked to cancer.